PMID: 9442782Jan 27, 1998Paper

Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group

Ophthalmology
P Watson

Abstract

The aim of the study was to assess the efficacy and safety of latanoprost in the long-term treatment of glaucoma. The study was designed as a randomized, 6-month double-masked parallel group, multicenter study comparing latanoprost with timolol followed by an 18-month open-label, multicenter study in which all patients were treated with latanoprost. In total, 277 patients were treated with latanoprost for up to 24 months. For the first 6 months of treatment, latanoprost (0.005%) administered once daily was compared with timolol (0.5%) administered twice daily. Patients then received latanoprost (once daily) for an 18-month follow-up period regardless of their initial treatment. Intraocular pressure (IOP) was measured over the 24-month treatment period, and any ocular-systemic symptoms or adverse events were evaluated. Latanoprost significantly reduced (P < 0.001) IOP by approximately 8 mmHg from pretreatment values, and this reduction was maintained over the 24-month treatment period with no sign of upward drift. Latanoprost is apparently free of any systemic side effect. The most significant ocular side effect with latanoprost was an increase in iris pigmentation, which occurred in 51 patients. Latanoprost, administered once d...Continue Reading

Citations

Dec 21, 2004·Advances in Therapy·Naris KitnarongAlexander R Kent
Jan 18, 2006·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Esther Arranz-Marquez, Miguel A Teus
Oct 17, 2006·Wiener medizinische Wochenschrift·Hemma Resch, Gerhard Garhofer
Apr 11, 2006·Japanese Journal of Ophthalmology·Yoko IkedaShigeru Kinoshita
Sep 3, 2002·Survey of Ophthalmology·Philip F J Hoyng, Yoshi Kitazawa
Sep 3, 2002·Survey of Ophthalmology·Robert A SchumerAgneta K Mandahl
Sep 3, 2002·Survey of Ophthalmology·Michael DiestelhorstCarol B Toris
Jan 16, 2002·Prostaglandins & Other Lipid Mediators·Luc CrevitsKoen Paemeleire
Sep 5, 2002·Ophthalmology·Stefano MigliorUNKNOWN European Glaucoma Prevention Study Group
Oct 22, 2002·Journal of Cataract and Refractive Surgery·Patrick C Yeh, Saras Ramanathan
Jul 9, 2002·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Warren J Scherer
Jun 29, 2000·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·W C StewartK T Holmes
Feb 15, 2000·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·D A LeeC Abrams
Feb 19, 2005·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Michael S KookJiyong Chung
Sep 7, 2007·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Viney GuptaRamanjit Sihota
May 26, 2006·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Warren J Scherer
Oct 19, 2007·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Warren J Scherer
Oct 28, 2009·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Mei TsudaMiyo Matsumura
Jan 22, 2002·The British Journal of Ophthalmology·Tin AungSteve K L Seah
Oct 6, 2001·BMJ : British Medical Journal·M MitraT James
Mar 9, 2011·Clinical Ophthalmology·Jaime Pablo Kelly RigolletLaura Lop
Oct 20, 2000·American Journal of Veterinary Research·M E StuderJ Stiles
Aug 12, 2009·Survey of Ophthalmology·Marla B SultanPaul P Lee
Oct 28, 2014·Clinical and Experimental Pharmacology & Physiology·Shani GolanShimon Kurtz
Feb 20, 2007·Ophthalmology·Esther Arranz-Marquez, Miguel A Teus
May 23, 2008·Acta Ophthalmologica·William C StewartBonnie Kruft
Nov 30, 1999·American Journal of Ophthalmology·R G FiscellaM Viana
Feb 26, 2016·Advances in Therapy·Anastasios G P KonstasStefano Miglior

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved